Evidence map›Paper›PMID 31603352›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2019

BDNF downregulates β-adrenergic receptor-mediated hypotensive mechanisms in the paraventricular nucleus of the hypothalamus.

Daniella Thorsdottir, Nicholas C Cruickshank, Zachary Einwag, Grant W Hennig, Benedek Erdos

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Daniella ThorsdottirDepartment of Pharmacology, University of Vermont, Burlington, Vermont.
Nicholas C CruickshankDepartment of Pharmacology, University of Vermont, Burlington, Vermont.
Zachary EinwagDepartment of Pharmacology, University of Vermont, Burlington, Vermont.
Grant W HennigDepartment of Pharmacology, University of Vermont, Burlington, Vermont.
Benedek ErdosDepartment of Pharmacology, University of Vermont, Burlington, Vermont.ORCID 0000-0002-9074-2491
University of Vermont · US

Funding

Brain-derived neurotrophic factor: a novel regulator of cardiovascular function in the hypothalamusR01HL133211 · NHLBI · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI ERDOS, BENEDEK · 2017 to 2020
$1.9M
NHLBI NIH HHS R01 HL133211
6 · The paper itself

Abstract

Brain-derived neurotrophic factor (BDNF) is upregulated in the paraventricular nucleus of the hypothalamus (PVN) in response to hypertensive stimuli such as stress and hyperosmolality, and BDNF acting in the PVN plays a key role in elevating sympathetic activity and blood pressure. However, downstream mechanisms mediating these effects remain unclear. We tested the hypothesis that BDNF increases blood pressure, in part by diminishing inhibitory hypotensive input from nucleus of the solitary tract (NTS) catecholaminergic neurons projecting to the PVN. Male Sprague-Dawley rats received bilateral PVN injections of viral vectors expressing either green fluorescent protein (GFP) or BDNF and bilateral NTS injections of vehicle or anti-dopamine-β-hydroxylase-conjugated saporin (DSAP), a neurotoxin that selectively lesions noradrenergic and adrenergic neurons. BDNF overexpression in the PVN without NTS lesioning significantly increased mean arterial pressure (MAP) in awake animals by 18.7 ± 1.8 mmHg. DSAP treatment also increased MAP in the GFP group, by 9.8 ± 3.2 mmHg, but failed to affect MAP in the BDNF group, indicating a BDNF-induced loss of NTS catecholaminergic hypotensive effects. In addition, in α-chloralose-urethane-anesthetized rats, hypotensive responses to PVN injections of the β-adrenergic agonist isoprenaline were significantly attenuated by BDNF overexpression, whereas PVN injections of phenylephrine had no effect on blood pressure. BDNF treatment was also found to significantly reduce β

Indexed as

Adrenergic beta-AgonistsAdrenergic beta-AntagonistsAnimalsBrain-Derived Neurotrophic FactorDown-RegulationHypertensionIsoproterenolMaleParaventricular Hypothalamic NucleusRatsRats, Sprague-DawleyReceptors, Adrenergic, betaSaporinsSynaptic TransmissionAdrenergic beta-AgonistsAdrenergic beta-AntagonistsBrain-Derived Neurotrophic FactorIsoproterenolReceptors, Adrenergic, betaSaporinsblood pressurebrain-derived neurotrophic factorcatecholaminehypothalamusβ-adrenergic receptors

Identifiers

PMID31603352
PMCPMC6962618
OpenAlexW2980211442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.